Study of Subclinical Viral Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Chronic allograft injury is the leading cause of graft loss in renal transplantation. The shortage of available kidneys for transplantation has reached crisis levels with increasing numbers of waiting list mortalities. Strategies to prolong graft survival are urgently needed. The pediatric and young adult transplant population is one in which repeat transplantation is inevitable and therefore, this group is one who will especially benefit from intervention to prolong graft survival. The hypothesis of this proposal is that subclinical viral infection is a modifiable risk factor in the pathogenesis of chronic allograft injury. The young age of the proposed study population is an ideal one to evaluate this objective due to the high prevalence of seronegative recipients. The studies outlined will determine the temporal relationship betWeween subclinical viremia, renal allograft infection and allograft injury. This will be the first prospective study in renal transplant recipients to systematically monitor subclinical viral infection both in peripheral blood and in the renal allograft with concurrent quantitative measures of renal function, allograft fibrosis, and innate immune activation. The investigators have chosen these 3 outcomes because they evaluate a spectrum of renal allograft injury and represent different stages - from early to late - in the pathophysiology that leads to renal allograft dysfunction. In addition, the role of virus specific T cell immune responses in the control of subclinical viral infection and associated allograft injury will be determined. These data are critical as they will provide insights into the pathogenesis of injury and will guide development of interventions strategies. Importantly, the current treatment strategies for viral disease do not prevent subclinical viral infection. Thus, the results of this study may identify that prevention, prophylaxis and/or treatment of subclinical viral replication as a long term strategy to prevent chronic allograft injury and prolong graft survival.
| Condition |
|---|
|
Kidney Transplantation Kidney Failure, Chronic |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Subclinical Viral Infection and Renal Allograft Injury |
- Change in measured GFR from baseline [ Time Frame: time of transplant, one time between months 3 and 6, and during months 12, and 24 after the transplant ] [ Designated as safety issue: No ]Single infusion of iohexol clearance to measure GFR
- Change in interstitial fibrosis and tubular atrophy of renal allograft from baseline [ Time Frame: Renal biopsies will be performed at time of transplant, 3-6 m, 12m, and 24m post-transplant. Precise measures of renal function, allograft fibrosis, and innate immune activation will be performed at baseline, 6m, 12, 24m post-transplant. ] [ Designated as safety issue: No ]
- Change in innate immune activation of renal allograft from baseline [ Time Frame: 6, 12, and 24 months after the transplant ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
If participant agrees, blood, tissue, and study data will be banked at Seattle Children's Research Institute.
| Estimated Enrollment: | 100 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | October 2016 |
| Estimated Primary Completion Date: | October 2016 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 1 Year to 25 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Pediatric and young adult renal transplant recipients (1<25yrs) of their first kidney transplant from Seattle Children's Hospital and University of Washington Medical Center.
Inclusion Criteria:
- Subject and/or parent guardian must be able to understand and provide informed consent or assent
- Male or Female, Seattle Children's Hospital participants must be 1-<21 yrs and University of Washington Medical Center participants 18-25yrs.
- Diagnosed with End Stage Renal Disease (ESRD)
Exclusion Criteria:
- Inability or unwillingness of subject and/or parent guardian to provide informed consent
- Pregnancy
Contacts and Locations| Contact: Jodi Smith, MD | 206-987-2524 | jodi.smith@seattlechildrens.org |
| Contact: Shannon Granillo | 206-884-1418 | shannon.granillo@seattlechildrens.org |
| United States, Washington | |
| Seattle Children's Hospital | Recruiting |
| Seattle, Washington, United States, 98105 | |
| Principal Investigator: | Jodi Smith, MD | Seattle Children's Hospital |
More Information
No publications provided
| Responsible Party: | Jodi Smith, Assistant Professor, Seattle Children's Hospital |
| ClinicalTrials.gov Identifier: | NCT01615341 History of Changes |
| Other Study ID Numbers: | R01DK088914-01a1 |
| Study First Received: | June 6, 2012 |
| Last Updated: | June 7, 2012 |
| Health Authority: | United States: Federal Government |
Keywords provided by Seattle Children's Hospital:
|
Kidney transplantation Subclinical Viral Infection Renal Allograft Injury |
Additional relevant MeSH terms:
|
Kidney Failure, Chronic Renal Insufficiency Virus Diseases |
Renal Insufficiency, Chronic Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013